CLINICAL & PIPELINE·Clinical Trial Initiation
Duboce Biopharmaceuticals Initiates Phase 1a/1b Clinical Trial for Novel Biologic DBC-664 in Advanced Solid Tumors
Duboce Biopharmaceuticals, Inc. has commenced a Phase 1a/1b clinical trial (NCT07705035) for its novel biologic, DBC-664, targeting advanced solid tumors. This first-in-human study, recruiting 210 patients, will assess safety, pharmacokinetics, and preliminary anti-tumor activity. This move signals Duboce's strategic entry into the competitive oncology market, impacting future development and partnership opportunities for stakeholders.
90-Day Activity